CHIMÄRER ANTI-CD20 ANTIKÖRPER, RITUXAN, ZUR VERWENDUNG IN DER BEHANDLUNG DER CHRONISCHEN LYMPHATISCHEN LEUKEMIE

摘要

A method of treating hematologic malignancies associated with a high number of circulating tumor cells by the administration of a therapeutic chimeric anti-CD20 antibody. These malignancies include in particular B-prolymphocytic leukemia (B-PLL), chronic lymphocytic leukemia (CLL), and transformed non-Hodgkin's lymphoma.